adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis
Published 11 years ago • 1K plays • Length 10:13Download video MP4
Download video MP3
Similar videos
-
5:14
one thousand patients with primary myelofibrosis: the mayo clinic experience
-
2:14
ruxolitinib combinations in patients with myelofibrosis
-
2:07
real-world use of ruxolitinib in patients with myelofibrosis with anemia or thrombocytopenia
-
1:22
real-world outcomes of patients with mf treated with fedratinib post-ruxolitinib discontinuation
-
2:10
management of ruxolitinib failure in myelofibrosis
-
6:03
survival data for patients younger than 60 with primary myleofibrosis
-
1:41
the efficacy of ruxolitinib re-treatment in patients with mf
-
22:26
what's your approach? treating myelofibrosis
-
1:59
pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
-
2:51
ruxolitinib treatment in myelofibrosis - video abstract: 24926
-
3:09
real-world data analysis of ruxolitinib in myelofibrosis
-
3:20
comfort: five-year outcomes of ruxolitinib in patients with myelofibrosis
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
2:30
zilurgisertib as monotherapy or in combination with ruxolitinib in patients with mf-related anemia
-
4:37
long-term survival and adverse effects with ruxolitinib
-
2:39
a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
-
3:21
manifest: ruxolitinib plus pelabresib for jak-inhibitor naïve myelofibrosis
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis